New study estimates 573,000 birds died at wind farms last year Wind farm in North Palm Springs, California, by Wendell (Creative Commons). Scientists who estimate how many birds are killed by wind turbines each year must factor in several variables: Dead birds can be difficult to find or are carried away by scavengers; search efforts vary from wind farm to wind farm; and power companies often keep fatality data confidential. The most recent number, published by analyst K. Shawn Smallwood in the March 2013 issue of the Wildlife Society Bulletin, is the highest to date. He estimates that in 2012 turbines across the United States killed 573,000 birds, including 83,000 raptors. The number of bats killed, he reports, was even higher: 888,000. Just as shocking, because thousands of additional megawatts of capacity were planned or under construction in 2012, he writes, “the annual toll on birds and bats will increase.” Smallwood’s number of bird deaths represents a 30 percent jump over the 440,000 fatalities estimated by a 2009 U.S. Fish and Wildlife Service report (pdf). Noting that his estimates were likely depressed by the incomplete availability of fatality reports, especially from Texas, Smallwood calls for transparency in reporting wildlife monitoring and for a standard method of detecting and estimating bird and bat deaths, so future totals do not rely on “post hoc mathematical adjustments.” His research was published just as the U.S. Department of the Interior and its agencies issued or were considering permits for wind-power companies to kill iconic and, in some cases, endangered bird species: • The Interior Department may allow companies to apply for unprecedented 30-year permits to kill a set number of Bald or Golden Eagles at wind farms. The proposal is said to be under review at the White House. • The Fish and Wildlife Service may permit a proposed 100-turbine wind farm located in the prairie potholes region of North Dakota to kill endangered Whooping Cranes and threatened Piping Plovers. • And in late May, the Bureau of Land Management and Fish and Wildlife said they would grant, for the first time, a wind farm the ability to kill an endangered California Condor without danger of prosecution. Splat!
yikes what happened after hours? Slinger Bag Inc OTCMKTS: SLBG 3.34 USD +0.27 (8.79%)today Closed: Sep 29, 4:24 PM EDT · Disclaimer After hours 2.75 −0.59 (17.66%) edit...maybe it was a just a low-ish volume drop? i don't see any news...
Hey Birds or Energy we have to choose. We can release more birds. Sea Birds as well we all know are a little stupid. A little slow to adapt. It's not like wind turbines are killing wood birds or Ct birds...
BioDelivery Sciences to host ELYXYB Investor Day 08:12 BDSI BioDelivery Sciences… Watch this today BDSI is a good company.
He's Baaaaaaack--- Aemetis signs offtake agreement with Delta for 250M gallons of SAF 08:10 AMTX, DAL GET HIGH! Lithium Americas initiated with an Overweight at JPMorgan 08:06 LAC JPMorgan analyst Tyler Langton initiated coverage of Lithium Americas with an Overweight rating and $28 price target. The analyst expects lithium prices to be supported by strong demand driving a greater supply/demand imbalance over the next decade. Lithium Americas is positioned favorably to take advantage of this price environment, Langton tells investors in a research note. Is today The day Van> YES! Genius Sports receives sports betting license in Connecticut 08:06 GENI -damn it Van these Elys guys are so rinky dink!!! Some fucking Bar!!! Elys Game Technology, Grand Central announce opening date for sports betting 08:04 ELYS Elys Game Technology and Grand Central, an independently owned operator of the Grand Central Restaurant & Bar located in the Adams Morgan area of Washington, D.C., announced the official opening date of October 4 for patrons to place real-money sports bets within the restaurant premises. WE NEED TO SWAP FROM ELYS INTO GENI.!!!!!!
Wow- Bicycle Therapeutics initiated with Buy, $56 target at B. Riley 08:13 BCYC BCYC-$39.50 (stoney stk from $15 sold out at $29)
View's Smart Windows chosen by Ah Haa School for new facility 07:07 VIEW Zevia initiated with an Outperform at Telsey Advisory 05:25 ZVIA Amicus upgraded to Overweight from Neutral at JPMorgan 05:16 FOLD Aemetis(NASDAQ:AMTX)+22% signs offtake agreement with Delta Air Lines for 250 million gallons of sustainable aviation fuel Broadwind(NASDAQ:BWEN) +6% sees sequential order growth of 50% in Q3; secures $12M in new orders Amicus Therapeutics(NASDAQ:FOLD)+5% U.S. FDA accepts filings for amicus’ AT-GAA for the treatment of pompe disease Up Another 15% yest... LICY Li-Cycle Holdings seen as poised for breakout after landing key investment Morgan Stanley weighs in on Li-Cycle Holdings Corp.(NYSE:LICY)attracting a $100M investment from Koch Strategic Platforms in the form of a convertible note. The firm says it is encouraged to see LICY taking action to increase the size and aim to improve the efficiency of its Spoke-and-Hub footprint. Analyst Adam Jonas: "As one of the world's largest private companies, we believe Koch can offer Li-Cycle significant expertise and the ability to leverage Koch's scale, while also providing a technical validation in the work being done on both sides. We see it as a win-win for LICY." The funding is seen as giving Li-Cycle (LICY) room to execute on its business plan and carve out a place in the EV battery recycling ecosystem. Morgan Stanley keeps an Overweight rating on LICY and price target of $15. Shares of Li-Cycle (LICY) are down 0.95% premarket after popping more than 14% yesterday on the heels of the Koch investment announcement.
This stock bugs me. TA. I had this for over a year at $31-$32 I mean it may have been two years! I gave up. It never moved. Never ever took off. ->Now it Dopes! TA TravelCenters of America Inc. 50.00 +1.75(+3.63%)
BDSI-- If you are going to have an analyst day it's good to have something to talk about. This interests me-- Investor Dayon October 14, 2021 RALEIGH, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it has completed the acquisition of U.S. and Canadian rights to ELYXYB™ (celecoxib oral solution) from Dr. Reddy’s Laboratories Limited. ELYXYB is the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. BDSI intends to launch ELYXYB in the first quarter of 2022. Additionally, BDSI plans to conduct an ELYXYB pediatric study, which will have the potential to address the significant unmet needs of pediatric and adolescent patients suffering from migraine attacks. Migraine is a debilitating condition for almost 40 million people in the U.S. Many acute migraine sufferers are searching for treatments that provide relief quickly and conveniently. “The availability of ELYXYB represents a significant therapeutic development for the acute treatment of migraine,” stated Richard Lipton, MD, Edwin S. Lowe Chair in Neurology at Albert Einstein College of Medicine, Director of the Montefiore Headache Center, and one of the clinical investigators for the ELYXYB studies. “With rapid onset of action delivered in a unique, ready-to-use oral solution, ELYXYB provides a convenient, quick relief treatment option to help patients return to functioning in their everyday lives.” ELYXYB is an oral solution of celecoxib, formulated using a self-micro emulsifying drug delivery system that improves solubility and bioavailability of the drug leading to better absorption1. This allows for the administration of a lower dose of drug to achieve therapeutic effect relative to a conventional oral solid dosage form. For adult patients who suffer from the debilitating and disruptive effects of migraine, there continues to be a need for reliable and efficacious treatment options. ELYXYB’s unit-dose oral solution makes it convenient for patients to take it immediately upon emergence of acute migraine attacks. “ELYXYB’s pivotal studies showed that the percentage of patients achieving Most Bothersome Symptom (MBS) freedom at two hours post-dose was significantly greater for those patients receiving ELYXYB versus those receiving placebo. Study 2 demonstrated that the percentage of patients reaching headache pain freedom two hours post-dose was significantly greater for those receiving ELYXYB versus those receiving placebo. The data also showed meaningful speed of onset with Tmaxachieved in approximately 60 minutes,” said Thomas Smith, MD, Chief Medical Officer at BDSI, and a former thought leader in the migraine space. “BDSI looks forward to expanding our impact in Migraine and to deepening our commitment to our patients-first philosophy.” << What is significantly better? We will find out today. 52%? language a little wishy washy >> “The acquisition of ELYXYB represents a critical step to building our presence in Neurology which is an excellent strategic adjacency to our pain franchise,” said Jeff Bailey, CEO of BDSI. “We are confident that ELYXYB will contribute to BDSI’s revenue growth and profitability over time, with patent protection until 2036. Our extensive commercial expertise, robust corporate infrastructure, and strong financial position will allow us to successfully commercialize ELYXYB and continue to pursue additional value-enhancing business development opportunities,” Bailey indicated. BDSI will host an Investor Day on October 14, 2021, to discuss ELYXYB in further detail.